US EditionGame-Changing Cancer Treatment Results: Innovent's 7 Breakthrough Presentations Reveal New Hope at ASCO 2025
- Innovent Biologics presents clinical data at the ASCO 2025 meeting in Chicago.
- The company develops innovative medicines for diseases like cancer.
- Presentations include data for bispecific antibody IBI363 and ADC molecule IBI343.
- Three IBI363 indications and IBI343 pancreatic cancer data received oral slots.
- These presentations showcase progress in bispecific antibodies and PD-1 immunotherapy.
32 Articles
32 Articles
Fear of Needles? Innovation would replace intravenous cancer drugs with pills
San Antonio, Texas.- A team of scientists from the University of Texas at San Antonio (UT Health San Antonio) developed an invention that could revolutionize the treatment of diseases such as brain cancer and Alzheimer's, by succeeding in replacing intravenous drugs with oral pills.This advance represents a significant step towards a more accessible, personalized and effective medicine. Currently, many medicines for serious and difficult to trea…
Hanford Sentinel
Seven Oral Presentations: Innovent to Present Breakthrough Clinical Data of IBI363（PD-1/IL-2α-bias）and Other Novel Drug Candidates at the 2025 ASCO Annual Meeting
SAN FRANCISCO and SUZHOU,China, April 23, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major…
Revvity to Unveil VivoJect™ Image-guided Injection System at AACR
Revvity reports that it will unveil the VivoJect image-guided injection system at the AACR Annual Meeting in Chicago later this week. Paired with the Vega automated preclinical ultrasound system, the VivoJect system was designed for real-time imaging and precise operation. It streamlines in vivo imaging workflows for applications such as tumor model creation, targeted drug delivery, gene therapy, stem cell research, and cardiac studies, accordin…
#Pfizers Forward Momentum in Cancer Care Amid Setbacks in Other Drug Developments
In an exciting and promising announcement, Pfizer Inc. (NYSE: PFE) has spotlighted its latest advancements in oncology at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Scheduled from May 30 to June 3 in Chicago, Pfizer will present data from more than 60 research abstracts, including 9 oral and 6 rapid oral presentations that delve into their innovative cancer medicines. This comprehensive showcase will highlight…
Coverage Details
Bias Distribution
- 85% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
